Says 2026 will be a year of accelerated impact and growth. Says heavier investment is expected to occur in first half of the year. Says Icotyde can be one of the company’s largest products ever. Says Tremfaya holds really unique and distinct position as first choice biologic. Says really excited about Icotyde and Tremfaya going forward. Says navigating dynamic world and market like everyone else. Says pleased with operational medtech growth. Says saw some medtech procedural softness in Q1, but nothing material. Comments and guidance taken from Q1 earnings conference call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Morning Movers: Globalstar climbs following deal to be acquired by Amazon
- Johnson & Johnson boosts outlook and raises dividend
- Johnson & Johnson Earnings: JNJ Stock Slips on Modest 2026 Sales Forecast despite Q1 Beat
- Options Volatility and Implied Earnings Moves Today, April 14, 2026
- Johnson & Johnson raises quarterly dividend 3.1% to $1.34 from $1.30 per share